Cultured human gingival fibroblasts treated with thymosin beta4
How the study was set up
Human gum fibroblasts in culture were challenged with inflammatory signals, bacterial components, or substances used in oral-care preparations.
What the researchers measured
IL-8 secretion, survival, and programmed cell death were assessed with and without thymosin beta4.
How to read this evidence
Researchers studied cells, isolated tissue, or animals. These experiments can help explain a mechanism, but do not establish benefits or safety in people. Human cells grown in a laboratory also belong in this category.
Results in context
Protection differed by challenge: some inflammatory and chemical effects changed, while bacterial lipopolysaccharide challenges did not. This does not establish general antimicrobial or gum-treatment benefit.
What this does not establish
Protection was stimulus-dependent in a cell culture. This is neither a human oral-health trial nor direct TB-500 evidence.
This collection includes related thymosin beta4 research. Parent or engineered peptide findings do not establish that a TB-500 fragment or a product sold under that name has the same effects.
Publication & source
Why this paper is included
The title focuses on thymosin beta4 or TB-500; parent-peptide findings do not establish TB-500 fragment effects.
Publication indexing
Journal Article · Research Support, Non-U.S. Gov't